240 related articles for article (PubMed ID: 36587744)
61. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
Front Immunol; 2021; 12():745320. PubMed ID: 34712233
[TBL] [Abstract][Full Text] [Related]
62. Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy.
Wudhikarn K; Tomas AA; Flynn JR; Devlin SM; Brower J; Bachanova V; Nastoupil LJ; McGuirk JP; Maziarz RT; Oluwole OO; Schuster SJ; Porter DL; Bishop MR; Riedell PA; Perales MA
Blood Adv; 2023 Jul; 7(13):3192-3198. PubMed ID: 36355838
[TBL] [Abstract][Full Text] [Related]
63. Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia.
Shahid S; Ramaswamy K; Flynn J; Mauguen A; Perica K; Park JH; Forlenza CJ; Shukla NN; Steinherz PG; Margossian SP; Boelens JJ; Kernan NA; Curran KJ
Transplant Cell Ther; 2022 Feb; 28(2):72.e1-72.e8. PubMed ID: 34852305
[TBL] [Abstract][Full Text] [Related]
64. Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma.
Mirza AS; Kumar A; Hashmi H; Garcia F; Logothetis CN; Darwin A; Faramand R; Reid K; Bachmeier C; Chavez JC; Shah B; Pinilla-Ibarz J; Khimani F; Lazaryan A; Liu H; Davila ML; Nishihori T; Locke FL; Jain MD
Transplant Cell Ther; 2021 Mar; 27(3):242.e1-242.e6. PubMed ID: 33781520
[TBL] [Abstract][Full Text] [Related]
65. [Long-term follow-up of humanized and murine CD19 CAR-T-cell therapy for B-cell acute lymphoblastic leukemia].
Du MY; Zhang YQ; Liao DY; Xie W; Xiong W; Mei H; Hu Y
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):793-799. PubMed ID: 38049329
[No Abstract] [Full Text] [Related]
66. Prognostic differences of refractory/relapsed nodal and extranodal diffuse large B-cell lymphoma in the chimeric antigen receptor T cell therapy era.
Song Z; Xu L; Tang G; Gao L; Wang L; Ni X; Chen L; Chen J; Wang T; Feng D; Yu X; Yang J; Wang Y
Clin Chim Acta; 2022 Jul; 532():72-78. PubMed ID: 35660013
[TBL] [Abstract][Full Text] [Related]
67. Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response by
Lutfi F; Goloubeva O; Kowatli A; Gryaznov A; Kim DW; Dureja R; Margiotta P; Matsumoto LR; Bukhari A; Ahmed N; Mushtaq MU; Law JY; Lee ST; Kocoglu MH; Atanackovic D; Yared JA; Hardy NM; McGuirk JP; Rapoport AP; Chen W; Dahiya S
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):757-763. PubMed ID: 37453865
[TBL] [Abstract][Full Text] [Related]
68. Costs, effectiveness, and safety associated with Chimeric Antigen Receptor (CAR) T-cell therapy: Results from a comprehensive cancer center.
Chacim S; Monjardino T; Cunha JL; Medeiros P; Redondo P; Bento MJ; Mariz JM
PLoS One; 2022; 17(12):e0278950. PubMed ID: 36490296
[TBL] [Abstract][Full Text] [Related]
69. ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Diffuse Large B-cell Lymphoma after Failure of Chimeric Antigen Receptor T Cell Therapy (CAR-T) Therapy.
Ahmed N; Kumar A; Kharfan-Dabaja MA; DeFilipp Z; Herrera A; Hashmi S; Dholaria B; Perales MA; Carpenter PA; Hamadani M
Transplant Cell Ther; 2022 Sep; 28(9):523-529. PubMed ID: 35671986
[TBL] [Abstract][Full Text] [Related]
70. Incorporating radiation with anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory non-Hodgkin lymphoma: A multicenter consensus approach.
Saifi O; Lester SC; Breen WG; Rule WG; Lin Y; Bennani NN; Rosenthal A; Munoz J; Murthy HS; Kharfan-Dabaja MA; Peterson JL; Hoppe BS
Am J Hematol; 2024 Jan; 99(1):124-134. PubMed ID: 37950857
[TBL] [Abstract][Full Text] [Related]
71. Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
Yuan X; Li X; Huang Y; Jin X; Liu H; Zhao A; Zhang W; Qian W; Liang Y
Front Immunol; 2022; 13():1015081. PubMed ID: 36505470
[TBL] [Abstract][Full Text] [Related]
72. Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes.
Figura NB; Sim AJ; Jain MD; Chavez JC; Robinson TJ
Expert Rev Hematol; 2022 Dec; 15(12):1023-1030. PubMed ID: 36369950
[TBL] [Abstract][Full Text] [Related]
73. The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma.
Lutfi F; Holtzman NG; Kansagra AJ; Mustafa Ali M; Bukhari A; Yan J; Samanta S; Gottlieb D; Kim DW; Matsumoto LR; Gahres N; Ruehle K; Lee ST; Law JY; Kocoglu MH; Atanackovic D; Yared JA; Hardy NM; Molitoris J; Mohindra P; Rapoport AP; Dahiya S
Br J Haematol; 2021 Nov; 195(3):405-412. PubMed ID: 34500492
[TBL] [Abstract][Full Text] [Related]
74. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.
Levin A; Shah NN
Am J Hematol; 2019 May; 94(S1):S18-S23. PubMed ID: 30652353
[TBL] [Abstract][Full Text] [Related]
75. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
[TBL] [Abstract][Full Text] [Related]
76. CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies.
Liang Y; Liu H; Lu Z; Lei W; Zhang C; Li P; Liang A; Young KH; Qian W
J Hematol Oncol; 2021 Feb; 14(1):26. PubMed ID: 33593414
[TBL] [Abstract][Full Text] [Related]
77. Integrating CAR-T cell therapy into the management of DLBCL: what we are learning.
Martino M; Canale FA; Porto G; Verduci C; Utano G; Policastro G; Germanò J; Alati C; Santoro L; Imbalzano L; Pitea M
Expert Opin Biol Ther; 2023; 23(12):1277-1285. PubMed ID: 38078446
[TBL] [Abstract][Full Text] [Related]
78. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.
Hunter BD; Rogalski M; Jacobson CA
Expert Opin Biol Ther; 2019 Nov; 19(11):1157-1164. PubMed ID: 31342797
[No Abstract] [Full Text] [Related]
79. Health Care Resource Utilization and Total Costs of Care Among Patients with Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy in the United States.
Keating SJ; Gu T; Jun MP; McBride A
Transplant Cell Ther; 2022 Jul; 28(7):404.e1-404.e6. PubMed ID: 35354101
[TBL] [Abstract][Full Text] [Related]
80. The acceleration of CAR-T therapy in non-Hodgkin lymphoma.
Munshi PN; Ujjani C
Hematol Oncol; 2019 Aug; 37(3):233-239. PubMed ID: 30427551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]